Nevro Corp. (NYSE:NVRO) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Calvin Chu - Morgan Stanley Simran Kaur - Piper Sandler Robbie Marcus - JPMorgan Danielle Antalffy - SVB Securities Joanne Wuensch - Citi Suraj Kalia - Oppenheimer David Rescott - Truist Securities Maggie Boeye ...

1Q 2022 Earnings Presentation M A Y 4 , 2 0 2 2 Dania Forward-Looking Statements In addition to historical information, this presentation contains forward-looking statements reflecting the company's current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: our second quarter and full-year 2022 financial guidance, including our expectations for PDN revenue in 2022; our expectations that the recent positive up ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R. ...

Financial Performance & Guidance - Worldwide revenue for Q4 2021 was $102.8 million, a decrease of 6% year-over-year, and a 10% decrease compared to Q4 2019[5] - U S revenue for Q4 2021 was $88.4 million, a decrease of 7% year-over-year, and a 10% decrease compared to Q4 2019[5] - Full-year 2021 worldwide revenue reached $386.9 million, a 7% increase year-over-year, but a 1% decrease compared to full-year 2019[5] - The company projects full-year 2022 revenue to be between $415 million and $430 million, which includes $25 million to $30 million from PDN revenue[16] - Non-GAAP Adjusted EBITDA for full-year 2022 is projected to be negative $8 million to negative $18 million[16] Strategic Initiatives & Market Position - The company received FDA approval for 10 kHz Therapy for Non-Surgical Refractory Back Pain (NSRBP)[6] - The company believes it is the only SCS company ahead of annual revenue compared to 2019, as of December 2021[10] - Launch initiatives for Painful Diabetic Neuropathy (PDN) are driving awareness, with PDN trials representing approximately 7% of total US trial volume in Q4 2021[6] - UnitedHealthcare's coverage decision for 10 kHz Therapy for PDN is expected to increase patient access[6] - Approximately 35% of PDN patients are covered as of March 1, 2022, following UnitedHealthcare's expansion[40] Market Opportunity - The total addressable U S lower back & leg market is estimated at $17.9 billion annually, with approximately 8% penetration[23] - The annual total addressable market for PDN is estimated to be ~$3.5-5.0 billion[30]

Nevro Corp. (NYSE:NVRO) Q4 2021 Earnings Conference Call February 23, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications and Investor Relations Officer Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Guggenheim Adam Maeder - Piper Sandler David Rescott - Truist Security Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 001-36715 NEVRO CORP. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Iden ...

Market Overview and Growth Potential - The Spinal Cord Stimulation (SCS) market has strong growth fundamentals despite being impacted by COVID-19 [5] - The global SCS market is estimated at $2.3 billion annually [11], with the US market accounting for $1.8 billion and the international market for $0.5 billion [12] - The total addressable U.S Lower Back & Leg market is $17.9 billion annually, with approximately 8% penetration [14] - The Non-Surgical Refractory Back Pain (NSRBP) market represents a $11.4 billion opportunity, with only ~5% penetration [17, 61] Nevro's Position and Strategy - Nevro is positioned to outperform in the SCS market with its unique 10 kHz Therapy [3, 67] - Nevro's SCS market share has been growing since 2015, reaching an estimated 18-20% [24] - U.S permanent procedures were up +4%, while total market SCS perms were down -8% [24] - The company is focused on expanding into Painful Diabetic Neuropathy (PDN) and NSRBP markets [6] Painful Diabetic Neuropathy (PDN) Opportunity - The annual Total Addressable Market (TAM) for PDN is estimated at $3.5-5.0 billion [37] - Approximately 20% of diagnosed Patients With Diabetes (PWD) have PDN, with 45% refractory to Conventional Medical Management (CMM) [37] - 86% of patients on 10 kHz Therapy had substantial, durable pain relief through 12 months, compared to 0% of patients on CMM alone [47] - Preliminary worldwide PDN revenue reached ~$4.0 million in Q4 2021 [57] Operational Efficiency and Financial Outlook - Excluding all litigation-related and PDN expenses, YTD Q3 2021 operating expenses would be less than YTD Q3 2019 by almost $35 million, or 13% [64] - Gross margin expansion to mid-70s% is expected over the next 3-5 years [65] - An investment of $21 million by the end of 2022 in Costa Rica manufacturing operations [65]

Q3 2021 Financial Performance - Worldwide revenue reached $93.2 million, a decrease of 14% year-over-year and 7% compared to Q3 2019[5] - U S revenue was $78.1 million, also down 14% year-over-year and 7% from Q3 2019[5] - International revenue amounted to $15.2 million, a 14% decrease as reported or 16% decrease in constant currency compared to the previous year, and a 5% decrease as reported or 12% decrease in constant currency compared to Q3 2019[5] - Gross margin was 69 3%, a decrease of 0 8% year-over-year and 0 5% compared to Q3 2019[5] - Operating expenses totaled $91.1 million, a 14% increase year-over-year and 6% increase compared to Q3 2019, excluding a $20 million patent litigation judgement[5] - Adjusted EBITDA was negative $6 0 million, a 144% decrease year-over-year and 201% decrease compared to Q3 2019[5] Q4 2021 Guidance - Revenue is projected to be between $94 million and $98 million, representing an 11% to 14% decrease compared to Q4 2020, and a 14% to 18% decrease compared to Q4 2019[16] - Non-GAAP adjusted EBITDA is expected to be negative $10 million to negative $13 million[16] Peripheral Neuropathy (PDN) Opportunity - The annual total addressable market (TAM) for PDN is estimated to be approximately $3 5 billion to $5 0 billion[23] - Nevro is the only company with a specific on-label indication from the FDA for treating PDN[27] Non-Surgical Refractory Back Pain (NSRBP) Opportunity - The total addressable market for NSRBP is $7 5 billion, with current market penetration at only 4%, representing a $300 million market[29, 30]

Nevro Corp. (NYSE:NVRO) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Julie Dewey - Vice President-Investor Relations and Corporate Communications Keith Grossman - Chairman, Chief Executive Officer and President Rod MacLeod - Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi Chris Pasquale - Guggenheim Tom Hopkins - Bank of America Robbie Marcus - JPMorgan Matt Taylor - UBS Daniel Antalffy - SVB Leerink David Rescott - Truist Security Suraj Kalia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-36715 Nevro Corp. (Exact name of registrant as specified in its charter) Delaware 56-2568057 (State or other jurisdiction of incorporation or organization) ( ...